Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
Completed
Eli Lilly and Company
Phase 3
2003-11-01
This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect
of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as
measured by hemoglobin A1c (HbA1c).
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
Completed
AstraZeneca
Phase 3
2003-11-01
This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect
of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as
measured by hemoglobin A1c (HbA1c).
Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms
Completed
University of Nottingham
N/A
2009-09-01
Exenatide is a new drug which lowers blood sugar (glucose) levels for people with type 2
diabetes. It has significant advantages over other treatments such as insulin as it causes
weight loss in a group of people that is generally overweight. Data from studies involving
exenatide have shown that it also has an effect on blood pressure. The mechanism for the
blood pressure lowering effect is not known and has not been investigated previously.
Exenatide may have an effect on blood vessels throughout the body and gut to reduce blood
pressure. 12 healthy men (18-45yr) will be studied on 2 occasions. Limb blood flow, skin
blood flow, gut blood flow, blood pressure, and heart rate will be measured half hourly for 4
hours. Blood samples (3ml) for insulin and glucose determination will be taken via a cannula
and 3-way tap at the same time points. A dose of either 5μg exenatide or saline will be
injected under the skin of the abdomen and a breakfast will be provided during the study. A
urine collection will be made over the duration of the study.
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Completed
Eli Lilly and Company
N/A
2010-01-01
Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to
speculate whether exenatide affects hepatic lipoprotein production in humans since there is
currently no evidence from animal models or in vitro studies that have demonstrated an effect
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
